WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407140
CAS#: 1609584-72-6
Description: MPS1-IN-3 is a selective and potent MPS1 inhibitor with phenotypic consequences similar to those reported for published MPS1 inhibitors such as MPS1-IN-1, MPS1-IN-2, and AZD3146. MPS1-IN-3 sensitizes glioblastoma cells to vincristine both in vitro and in murine tumor models. MPS1 may be a promising therapeutic target for high-grade glioma therapy and that MPS1 inhibition by MPS1-IN-3 efficiently sensitizes glioblastoma cells to antimitotic agents.
MedKoo Cat#: 407140
Name: Mps1-IN-3
CAS#: 1609584-72-6
Chemical Formula: C26H31N7O4S
Exact Mass: 537.21582
Molecular Weight: 537.64
Elemental Analysis: C, 58.08; H, 5.81; N, 18.24; O, 11.90; S, 5.96
Mps1-IN-3, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: Mps1-IN-3; Mps1 IN3; Mps1-IN3.
IUPAC/Chemical Name: 1-(4-((6-((2-(isopropylsulfonyl)phenyl)amino)-9H-purin-2-yl)amino)-3-methoxyphenyl)piperidin-4-ol
InChi Key: OFRMASLPWOMYHN-UHFFFAOYSA-N
InChi Code: InChI=1S/C26H31N7O4S/c1-16(2)38(35,36)22-7-5-4-6-20(22)29-25-23-24(28-15-27-23)31-26(32-25)30-19-9-8-17(14-21(19)37-3)33-12-10-18(34)11-13-33/h4-9,14-16,18,34H,10-13H2,1-3H3,(H3,27,28,29,30,31,32)
SMILES Code: OC1CCN(C2=CC=C(NC3=NC(NC4=CC=CC=C4S(=O)(C(C)C)=O)=C5N=CNC5=N3)C(OC)=C2)CC1
The following data is based on the product molecular weight 537.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Tannous BA, Kerami M, Van der Stoop PM, Kwiatkowski N, Wang J, Zhou W, Kessler AF, Lewandrowski G, Hiddingh L, Sol N, Lagerweij T, Wedekind L, Niers JM, Barazas M, Nilsson RJ, Geerts D, De Witt Hamer PC, Hagemann C, Vandertop WP, Van Tellingen O, Noske DP, Gray NS, Würdinger T. Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs. J Natl Cancer Inst. 2013 Sep 4;105(17):1322-31. doi: 10.1093/jnci/djt168. Epub 2013 Aug 12. PubMed PMID: 23940287; PubMed Central PMCID: PMC3760778.